Hodgkin Lymphoma
Also known as: Hodgkin Disease
Methodology & AI Transparency ⓘ
Hodgkin Lymphoma Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: What is Hodgkin lymphoma? Hodgkin lymphoma, also called Hodgkin disease, is a type of cancer that develops in the lymph system.
- 2 Real-world patient consensus: Diagnostic registry C81.2: Hodgkin Lymphoma is managed within Cancer & Oncology (aka Hodgkin Disease).
- 3 Typical cash cost range: Primary evaluation for Hodgkin Lymphoma incorporates tissue biopsy with in Hodgkin Lymphoma (C81.2: histopathology) and symptom diary review.
- 4 Top reported side effects / signs: Key Cancer & Oncology biomarkers for Hodgkin Lymphoma (C81.2): Comprehensive Metabolic & in Hodgkin Lymphoma (C81.2: Organ Function Panel) & Pathology / Molecular in Hodgkin Lymphoma (C81.2: Genomic Staging) (Guideline-concordant surveillance (C81.2)).
Ask our AI Specialists anything about Hodgkin Lymphoma
What Is Hodgkin Lymphoma?
What is Hodgkin lymphoma? Hodgkin lymphoma, also called Hodgkin disease, is a type of cancer that develops in the lymph system. Your lymph system is part of your immune system . It helps protect your body from infection and disease. The lymph system is made up of tissues and organs that produce, store, and carry white blood cells. It includes your: Bone marrow Lymph nodes Lymphatic vessels Spleen Thymus Tonsils Hodgkin lymphoma is one of the main types of lymphoma . The other is non-Hodgkin lymphoma. Each type starts in different types of white blood cells. What causes Hodgkin lymphoma? The cause of Hodgkin lymphoma is unknown.
Pathophysiology, Underlying Causes & Clinical Presentation
Biological expression of Hodgkin Lymphoma (C81.2, Cancer & Oncology) reflects potential lymphatic or in Hodgkin Lymphoma (C81.2: hematogenous dissemination if). Cross-referenced with NIH MeSH (Hodgkin Disease), longitudinal control is benchmarked via Comprehensive Metabolic & in Hodgkin Lymphoma (C81.2: Organ Function Panel).
Common Symptoms & Clinical Signs
- • Age. Hodgkin lymphoma is most common in early adulthood (age 20-39 years) and in late adulthood (age 65 years and older)
- • Being male. The risk of adult Hodgkin lymphoma is slightly higher in males than in females
- • Presentation of Hodgkin Lymphoma (C81.2): persistent painless lump, in Hodgkin Lymphoma (C81.2: non-healing ulcer/mole change,)
- • Secondary Hodgkin Lymphoma clinical sign: unintended weight loss [Hodgkin Lymphoma C81.2]
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Hodgkin Lymphoma Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | C81.2 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Cancer, Oncology & Supportive Care | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Comprehensive Metabolic & in Hodgkin Lymphoma (C81.2: Organ Function Panel) | Preserved renal/hepatic clearance (C81.2) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Pathology / Molecular in Hodgkin Lymphoma (C81.2: Genomic Staging) | Guideline-concordant surveillance (C81.2) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Complete Blood Count in Hodgkin Lymphoma (C81.2: (ANC, Hemoglobin, Platelets)) | Safe hematologic reserve (C81.2) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Hodgkin Lymphoma
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Rituximab Rituxan • RxCUI 1657862 | CD20-directed Cytolytic Antibody | 83% | $2.6200 | $ 114.61 /mo |
| Ensartinib Ensacove • RxCUI 2712634 | FDA Prescription Therapeutic Agent | 79% | $1.4600 | $ 67.63 /mo |
| Gallium Citrate Ga-67 Gallium Citrate Ga-67 Generic • RxCUI RXN-69945180-1786 | FDA Prescription Therapeutic Agent | 89% | $0.5500 | $ 30.78 /mo |
| Bexarotene Targretin • RxCUI 308725 | Retinoid | 84% | $1.6000 | $ 81.69 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Hodgkin Lymphoma)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Phase III Study to Evaluate real-world benefits and safety of Andecaliximab With: What a 432-Participant Study Found The addition of ADX to mFOLFOX6 did not improve OS in unselected patients with untreated human epidermal growth factor receptor 2-negative gastric or GEJ adenocarcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2021-03-20 • Phase III Randomized Trial | N = 432 | 93/100 | PMID 33577358 ↗ |
| Can This Approach Help? Inside the Latest Research on A Phase 1/2 Study of CAT-8015 in Adult Relapsed or Refractory B-Cell Non-Hodgkin Registered in the U.S. ClinicalTrials.gov Registry (NIH NLM) • 2013-03-04 • Completed Human Clinical Trial (NCT) | N = 23 | 89/100 | PMID NCT01030536 ↗ |
| Can This Approach Help? Inside the Latest Research on Lenalidomide Plus Rituximab for Relapsed/Refractory Indolent Non-Hodgkin Improved long-term efficacy with R 2 versus R-placebo and manageable safety with R 2 were observed in patients with FL, including those 70 years and older. Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2026-06-15 • Phase III Randomized Trial | N = 66 | 88/100 | PMID 41990300 ↗ |
| New Insights on Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously: What a 243-Participant Study Found The PUFFIN final analysis showed, per the primary analysis, that overall efficacy of pertuzumab plus trastuzumab and docetaxel was consistent with CLEOPATRA. Breast cancer research and treatment • 2023-02-15 • Phase III Randomized Trial | N = 243 | 88/100 | PMID 36463547 ↗ |
| Can This Approach Help? Inside the Latest Research on Pembrolizumab in relapsed or refractory Hodgkin lymphoma: a post hoc analysis of Data suggest pembrolizumab may be a promising second-line therapy for participants with R/R cHL ineligible for auto-SCT. Leukemia & lymphoma • 2025-09-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 40548833 ↗ |
Hodgkin Lymphoma Patient Community & “People Like Me” Threads
Filter Hodgkin Lymphoma community threads and patient logs by age, biological sex, dosage, and treatment duration.